Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Mega Genomics Limited ( (HK:6667) ) is now available.
Mega Genomics shareholders unanimously approved all resolutions at the 21 May 2026 annual general meeting, including adoption of the 2025 audited financial statements and the re-election of executive, non-executive and independent non-executive directors. The meeting also endorsed a final dividend of RMB0.15 per share, renewed mandates for share repurchases and new share issuance, reappointed the external auditor and authorized the board to set director and auditor remuneration, reinforcing governance continuity and capital management flexibility.
The decisive support across all votes, each receiving 100% approval from those present, signals strong investor confidence in the company’s leadership and strategic direction. By securing authority to buy back up to 10% of its issued shares and issue up to 20% new shares, Mega Genomics preserves room to optimize its balance sheet, pursue growth initiatives and manage dilution, while the cash dividend underscores a commitment to returning value to shareholders alongside continued investment in the business.
More about Mega Genomics Limited
Mega Genomics Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the genomics and life sciences sector. The company focuses on genetic testing and related services, targeting healthcare applications and consumer genomics in Greater China and broader Asian markets, leveraging its scientific expertise and regulatory approvals to expand its customer base.
Average Trading Volume: 6,348
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.59B
For detailed information about 6667 stock, go to TipRanks’ Stock Analysis page.